Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
NCT ID: NCT05155579
Last Updated: 2025-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
593 participants
INTERVENTIONAL
2022-05-14
2025-05-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
NCT03896724
Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali
NCT06080243
A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
NCT05790889
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
NCT02925403
R21/Matrix-M in African Children Against Clinical Malaria
NCT04704830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For groups 4 and 5, this is a randomised, open-label study to assess the safety and immunogenicity of R21/Matrix-M when co-administrated with various EPI vaccines at the relevant ages, in a malaria endemic area.
Group 6 is a randomised, open-label study to assess safety and immunogenicity of a delayed, third dose of R21/Matrix-M in 5-36 month old children, in a malaria endemic area.
For groups 1, 2, 3, 5 and 6, participants will be randomised 1:1. For group 4, participants will be randomised 3:3:1.
Approximately 590 children will be recruited across these six study groups.
The primary study objectives are:
Safety
* To assess the safety and reactogenicity of R21/Matrix-M, as a single- vial formulation in 5-36-month old African children.
* To assess the safety and reactogenicity of co-administration of R21/Matrix-M with the EPI vaccines given at 9 months, measles-rubella and yellow fever vaccines, in African children.
* To assess the safety and reactogenicity of co-administration of R21/Matrix-M with the EPI vaccines given at 6, 10 and 14 weeks of age, pentavalent and oral polio vaccine (OPV), in African children.
Immunogenicity
* To assess the immunogenicity of R21/Matrix-M, as a single- vial formulation in 5-36-month-old African children, compared with the two-vial formulation.
* To assess the immunogenicity of EPI vaccines given at 9 months, measles-rubella and yellow fever vaccines, when given with and without R21/Matrix-M
* To assess the immunogenicity of EPI vaccines given at 6, 10 and 14 weeks of age, pentavalent and oral polio vaccines, given as part of EPI at 6, 10 and 14 weeks of age, when given with and without R21/Matrix-M.
The secondary study objectives are:
* To assess the safety and reactogenicity of R21/Matrix-M, as a single- vial formulation in African children compared with the two-vial formulation.
* To assess the safety and reactogenicity of a delayed third dose of R21/Matrix-M in 5-36-month-old African children.
* To assess the immunogenicity of a delayed third dose of R21/Matrix-M in 5-36-month-old African children.
This trial is funded by the Serum Institute of India.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Groups 1a, 2a and 3a
60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a two vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1a is 20 children aged 5-11 months, group 2a is 20 children aged 12-23 months, and group 3a is 20 children aged 24-36 months.
R21/Matrix-M - two vial formulation
Adjuvanted malaria vaccine in a double vial formulation
Group 1b, 2b and 3b
60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a single vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1b is 20 children aged 5-11 months, group 2b is 20 children aged 12-23 months, and group 3b is 20 children aged 24-36 months.
R21/Matrix-M - single vial formulation
Adjuvanted malaria vaccine in a single vial formulation
Group 4a
150 participants, aged 6-7 months at the time of randomisation (to ensure third vaccination is given at approximately 9 months), who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart. At the time of the third dose they will receive their measles-rubella and yellow fever vaccinations at the same time as R21/Matrix-M.
R21/Matrix-M - single vial formulation
Adjuvanted malaria vaccine in a single vial formulation
Licensed vaccine - Measles-rubella
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Yellow fever
Licensed vaccine part of the EPI vaccination schedule
Group 4b
150 participants, aged 6-7 months at the time of randomisation, who will receive a measles-rubella and yellow fever vaccination 2 months after randomisation.
Licensed vaccine - Measles-rubella
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Yellow fever
Licensed vaccine part of the EPI vaccination schedule
Group 4c
Group 4c is 50 participants, aged 6-7 months at the time of randomisation, who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart.
R21/Matrix-M - single vial formulation
Adjuvanted malaria vaccine in a single vial formulation
Group 5a
30 children who will receive 3 doses of 5µg R21/50µg Matrix-M, pentavalent, rotavirus, pneumococcal and OPV vaccines at 6, 10 and 14 weeks of age. They will receive IPV two weeks following the third dose.
R21/Matrix-M - single vial formulation
Adjuvanted malaria vaccine in a single vial formulation
Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Oral Polio Vaccine (OPV)
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Rotavirus
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Pneumococcal vaccine
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Inactivated Polio Vaccine (IPV)
Licensed vaccine part of the EPI vaccination schedule
Group 5b
30 children who will receive 3 doses of pentavalent, rotavirus, pneumococcal and OPV vaccines at 6, 10 and 14 weeks of age. They will receive IPV two weeks following the third dose.
Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Oral Polio Vaccine (OPV)
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Rotavirus
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Pneumococcal vaccine
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Inactivated Polio Vaccine (IPV)
Licensed vaccine part of the EPI vaccination schedule
Group 6a
30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 6 months after the first dose.
R21/Matrix-M - single vial formulation
Adjuvanted malaria vaccine in a single vial formulation
Group 6b
30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 12 months after the first dose.
R21/Matrix-M - single vial formulation
Adjuvanted malaria vaccine in a single vial formulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
R21/Matrix-M - single vial formulation
Adjuvanted malaria vaccine in a single vial formulation
R21/Matrix-M - two vial formulation
Adjuvanted malaria vaccine in a double vial formulation
Licensed vaccine - Measles-rubella
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Yellow fever
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Oral Polio Vaccine (OPV)
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Rotavirus
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Pneumococcal vaccine
Licensed vaccine part of the EPI vaccination schedule
Licensed vaccine - Inactivated Polio Vaccine (IPV)
Licensed vaccine part of the EPI vaccination schedule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Group 1: The child is 5-11 months of age at the time of randomization (i.e. up to the day before of their first birthday).
* Group 2: The child is 12-23 months of age at the time of randomization (i.e. up to the day before of their second birthday).
* Group 3: The child is 24-36 months of age at the time of randomization (i.e. up to the day of their third birthday).
* Group 4: The child is 6-7 months of age at the time of randomization.
* Group 5: The child is 6 weeks of age at the time of randomization and have not received any dose of the pentavalent vaccine, pneumococcal vaccine, rotavirus vaccine, IPV and only the first dose of the OPV.
* Group 6: The child is aged 5-36 months at the time of their first vaccination
* Signed informed consent/thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child to join the trial.
* The investigator believes that the parents/guardians can and will comply with the requirements of the protocol if the child is enrolled in the study.
* The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial.
Exclusion Criteria
* The child is enrolled in another malaria intervention trial that could interfere with the results of this study.
* The child has a history of allergic disease or reactions likely to be exacerbated by any component of the study vaccines.
* The child has a history of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunisations.
* The child has major congenital defects.
* The child has anaemia associated with clinical signs of symptoms of decompensation, or a haemoglobin of ≤7.4 g/dL.
* The child has had a blood transfusion within one month of enrolment.
* The child has been administered immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
* The child has malnutrition requiring hospital admission.
* The child has an acute or chronic, clinically significant pulmonary, cardiovascular, gastrointestinal, endocrine, neurological, skin, hepatic or renal functional abnormality, as determined by medical history, physical examination or laboratory tests.
* Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV or asplenia.
* The child has received an investigational drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
* The child is currently participating in another clinical trial if likely to affect data interpretation of this trial
* The child has any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
* Clinically significant laboratory abnormality as judged by the study clinician
* For group 5 only: the child has received any dose of the pentavalent vaccine, pneumococcal vaccine, rotavirus vaccine, IPV or has received more than one dose of the OPV.
• Any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
6 Weeks
36 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Malaria Research and Training Center, Bamako, Mali
OTHER
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian Hill
Role: PRINCIPAL_INVESTIGATOR
University of Oxford
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Malaria Research & Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences Techniques and Technologies of Bamako
Bamako, , Mali
CCVTM, University of Oxford
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VAC088
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.